FDA Approved Products Developed with Technologies
from the Intramural Research Program
at the National Institutes of Health
|
Licensee |
Product |
FDA Approval Date / First Commercial U.S. Sale |
Berlex Laboratories |
Fludara® |
18 April 1991 / 1991 |
- A DNA polymerase inhibitor (fludarabine) that has been shown to have potent
activity in the treatment of B-cell leukemia. This compound is a cancer
chemotherapeutic drug, 2-F-araA.
|
Bristol Myers Squibb |
Videx® |
09 Oct 1991 / 1991 |
- A treatment of HIV infection with ddI. Selectively inhibits the replication
of HIV by interfering with a critical element known as reverse transcriptase.
Because of being better tolerated or having a different pattern of toxicity than
other treatments, patients may find it useful in either individual or combination
treatment therapy.
|
Hoffmann LaRoche |
Hivid® |
19 Jun 1992 / 1992 |
- A treatment of HIV infection with ddC. Inhibits the replication of HIV
by interfering with the critical enzyme reverse transcriptase. Patients find
it useful in either individual or combination treatment therapy.
|
Bristol Myers Squibb |
Taxol® |
29 Dec 1992 / 1996 |
- An improved method for administering Taxol® (paclitaxel) has significantly
improved the treatment of cancerous tumors, particularly advanced stage epithelial
ovarian and breast cancers. Paclitaxel is a compound derived from the bark of
the Western Yew tree.
|
MedImmune Inc. |
NeuTrexin® |
17 Dec 1993 / 1994 |
- A treatment using trimetrexate as an anti-parasitic agent for infection.
Infections due to Toxoplasma gondii and Pneumocystis carinii, as seen in AIDS
patients are extremely refractory to standard therapy can be effectively treated
by administering this drug.
|
GlaxoSmithKline |
Havrix® |
22 Feb 1995 / 1997 |
- A vaccine from the isolation of Hepatitis A virus strain HM-175.
Hepatitis A is probably the most widespread of viral hepatitis diseases
and is an endemic childhood disease in the underdeveloped countries of
the world.
|
Janssen Pharmaceuticals |
SPORANOX® Oral Solution |
21 Feb 1997 / 1997 |
- Oral formulation of the anti-fungal agent itraconazole that is used for
the treatment of painful and debilitating fungal infections of the esophagus
and mouth, commonly called thrush. Itraconazole is solubilized for this
application through coupling with hydroxy-propyl-cyclodextrin, a molecular
inclusion complex.
|
Protein Design Laboratory / Hoffman LaRoche |
ZENAPAX® |
10 Dec 1997 / 1998 |
- A humanized monoclonal antibody used for the prevention of acute kidney transplant
rejection. This recombinantly produced antibody achieves its immunosuppressive properties
by binding to the alpha (or Tac) subunit of human interleukin-2 (IL-2) receptor that is
expressed on the surface of activated lymphocytes.
|
MedImmune Inc |
Synagis® |
19 Jun 1998 / 1998 |
- A monoclonal antibody used for the prevention and treatment of serious lower respiratory
tract disease by respiratory syncytial virus (RSV). RSV is the most common cause of pneumonia
and bronchiolitis in infancy and early childhood. Synagis is the world's first monoclonal
antibody licensed by the FDA for any infectious disease.
|
Baxter Pharmaceuticals, formerly North American Vaccine, Inc. |
Certiva™ |
29 Jul 1998 / 1998 |
- A combined diphtheria, tetanus and acellular pertussis vaccine for use in infants and children.
A special process that reduces local and systemic adverse events commonly associated with traditional
whole-cell DPT vaccine administration has detoxified the acellular pertussis component of this vaccine.
Certiva™ is the first pediatric vaccine introduced into the U.S. market by a new independent vaccine
producer in over ten years. (Manufacturer has withdrawn the product from the market)
|
Isis Pharmaceuticals Inc |
Vitravene® |
26 Aug 1998 / 1998 |
- A phosphorothioate oligonucleotide that inhibits cytomeglovirus (CMV)
infections in the eye. Such infections commonly occur in immunocompromised
patients with resultant damage to the retina. Vitravene® is the first antisense
therapeutic approved for use in humans.
|
Wyeth Laboratories Inc. |
RotaShield® |
31 Aug 1998 / 1998 |
- A live oral vaccine for the prevention of rotavirus gastroenteritis in infants.
Rotavirus is the single most common cause of epidemic severe acute gastroenteritis
(diarrhea and vomiting) in infants and children from both developed and developing
countries. RotoShield® is the first rotavirus vaccine approved for use in humans.
(Manufacturer has withdrawn the product from the market)
|
Berlex Laboratories, formerly Diatide Inc. |
AcuTect® |
14 Sep 1998 / 1998 |
- A synthetic peptide radiopharmaceutical used for the detection of acute deep
venous thrombosis (DVT). DVT affects an estimated 5 million individuals in the U.S.
each year and is the most common source of pulmonary embolism. AcuTect® is the first
in-vivo imaging agent to target acute DVT in the lower extremities.
|
Genzyme Corp. |
Thyrogen® |
30 Nov 1998 / 1998 |
- A recombinant form of human thyroid stimulating hormone (TSH) for use in follow-up
screening of patients who have been treated for thyroid cancer. Thyrogen® permits these
patients to avoid the debilitating effects of thyroid hormone withdrawal while undergoing
standard diagnostic procedures such as serum thyroglobulin testing and radioiodine
imaging.
|
GlaxoSmithKline |
LYMErix™ |
21 Dec 1998 / 1999 |
- The world's first vaccine for the prevention of Lyme disease. Lyme disease is one
of the fastest vector-borne diseases in the US. It can lead to severe and debilitating
problems such as arthritis, heart abnormalities and Bell's palsy. (Manufacturer has
withdrawn the product from the market)
|
Berlex Laboratories, formerly Diatide Inc. |
NeoTect® |
03 Aug 1999 / 1999 |
- A synthetic peptide radiopharmaceutical used for the diagnosis of lung cancer.
The probe binds to somatostatin receptor-bearing masses in the lungs, and offers
additional information to the physician. The procedure, being minimally invasive,
carries much reduced risk compared to invasive procedures like biopsies.
(Manufacturer has withdrawn the product from the market)
|
MedImmune Inc./ Biotrin International |
Parvovirus B19 Enzyme Immunoassay |
06 Aug 1999 / 2001 |
- By detecting B19 virus IgM antibodies in human serum and plasma, this product should be
helpful in diagnosing and managing parvovirus B19 infection, which can put pregnant women at
serious risk of fetal loss. This is the first diagnostic test for parvovirus B19 infection
approved by the FDA for U.S. use.
|
GlaxoSmithKline |
Twinrix® |
11 May 2001 / 2001 |
- A vaccine formulation that combines both Hepatitis A and Hepatitis B. Combining the
two vaccines, for two of the most common infectious diseases that represent serious public
health problems, Twinrix® offers significant advantages such as increased convenience for
patient and physician, fewer injections and greater compliance compared with two separate
vaccines.
|
IDEC Pharmaceuticals |
Zevalin® |
19 Feb 2002 / 2002 |
- A treatment for non-Hodgkin's lymphoma, which affects 50,000 Americans annually.
A majority of these cases are low-grade lymphomas that do not respond to other treatments.
Treatment with Zevalin®, which is simple and fast, and has less severe side effects, is
especially suited for these patients. This drug combines the targeting power of monoclonal
antibodies with the cell killing ability of radioactive atoms, and is the first
radioimmunotherapy to be approved by the FDA.
|
Millennium Pharmaceuticals |
Velcade® |
13 May 2003 / 2003 |
- A treatment for multiple myeloma, that works by specifically inhibiting an enzyme
complex known as the proteosome. Under an accelerated approval program, the FDA has
allowed the use of Velcade in patients who have failed two prior therapies. The selectivity
and manageable side-effect profile of this boronic dipeptide compound makes it an exciting
new cancer drug. NIH researchers made a critical contribution by developing stable,
pharmaceutically acceptable compositions of these important compounds. Indeed, as the
first proteosome inhibitor to be approved by the FDA, Velcade® opens the door for a new
class of useful drugs.
|
Angiotech/Boston Scientific |
TAXUS™
Express2™ Monorail
Paclitaxel-Eluting Coronary Stent System |
04 Mar 2004 / 2004 |
- Treatment of coronary artery disease by balloon angioplasty and placement
of a stent is often followed by restenosis caused by cellular proliferation.
The TAXUS™ Express2™ stent system contains two medical components: the Express2
coronary stent and paclitaxel contained in a polymer coating. NIH researchers
discovered that the paclitaxel component inhibits cellular proliferation and
subsequent restenosis thus leading to greatly improved medical outcomes.
|
Barr Laboratories |
Didanosine Delayed-Release Capsules |
03
Dec 2004 / 2005 |
- Generic equivalent for Videx® EC, a treatment of HIV infection with ddI.
Selectively inhibits the replication of HIV by interfering with a critical element
known as reverse transcriptase. Because of being better tolerated or having a
different pattern of toxicity than other treatments, patients may find it useful
in either individual or combination treatment therapy.
|
Amgen Inc. |
Kepivance™ |
15
Dec 2004 / 2005 |
- Kepivance™ (palifermin)
is a human keratinocyte growth factor
protein produced using recombinant DNA
technology. It is used to decrease the
incidence and duration of severe mouth
sores in patients with hematologic cancers
who receive myelotoxic therapy. In such
a therapy, the patients' myeloid cells
are first destroyed by chemotherapy alone
or in combination with radiation, and
then reconstituted with a bone marrow
transplant. Kepivance™ is the first
and only therapy to treat the severe mouth
sores that afflict these patients as a
painful and unavoidable side effect of
the treatment.
|
Merck & Co. Inc. |
Gardasil® |
08 Jun 2006 / 2006 |
- A new vaccine to protect against cervical cancer, currently approved for use in females aged 9 to 26. Gardasil® prevents infection against four forms of Human Papilloma Virus (HPV): HPV16, HPV18, HPV6, and HPV11.
|
Tibotec Pharmaceuticals Ltd. |
Prezista™ |
23 Jun 2006 / |
- A novel protease inhibitor for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies. Prezista™ is approved for use in combination with low-dose administration of ritonavir, which helps decrease the breakdown of Prezista™ in the body, thereby enhancing drug efficacy.
|